MX2016009331A - Composiciones y metodos para tratar enfermedades oculares. - Google Patents
Composiciones y metodos para tratar enfermedades oculares.Info
- Publication number
- MX2016009331A MX2016009331A MX2016009331A MX2016009331A MX2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A
- Authority
- MX
- Mexico
- Prior art keywords
- ocular
- edema
- diseases
- methods
- neovascularization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se describen los métodos para tratar enfermedades o estados de los ojos, especialmente retinopatías, edema ocular y neovascularización ocular. Los ejemplos no limitativos de estas enfermedades o estados incluyen edema macular diabético, degeneración macular relacionada con la edad (forma húmeda o seca) , neovascularización coroidea, retinopatía diabética, oclusión de la vena (central o de las ramas) de la retina, traumatismo ocular, edema inducido por cirugía, neovascularización inducida por cirugía, edema macular cistoide, isquemia ocular, uveítis y similares. Estas enfermedades o estados se caracterizan por cambios en la vasculatura ocular, sean progresivos o no progresivos, resultado de una enfermedad o estado agudo o de una enfermedad o estado crónico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461930811P | 2014-01-23 | 2014-01-23 | |
PCT/US2015/012634 WO2015112831A1 (en) | 2014-01-23 | 2015-01-23 | Compositions and methods for treating ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009331A true MX2016009331A (es) | 2016-10-26 |
Family
ID=53681968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009331A MX2016009331A (es) | 2014-01-23 | 2015-01-23 | Composiciones y metodos para tratar enfermedades oculares. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160339005A1 (es) |
EP (1) | EP3096617A4 (es) |
JP (1) | JP2017503835A (es) |
KR (1) | KR20160108554A (es) |
CN (1) | CN106132201A (es) |
AU (1) | AU2015209264A1 (es) |
CA (1) | CA2937349A1 (es) |
IL (1) | IL246791A0 (es) |
MX (1) | MX2016009331A (es) |
RU (1) | RU2016133980A (es) |
WO (1) | WO2015112831A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3357911T (lt) | 2006-06-26 | 2022-08-10 | Akebia Therapeutics Inc. | Prolilo hidroksilazės inhibitoriai ir naudojimo būdai |
NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
BR112015031027A2 (pt) | 2013-06-13 | 2017-08-29 | Akebia Therapeutics Inc | Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única |
SG10202012791TA (en) | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用 |
MX2017012460A (es) | 2015-04-01 | 2018-01-30 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia. |
KR20180036580A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물 |
KR102252450B1 (ko) | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
ES2953875T3 (es) * | 2017-02-27 | 2023-11-16 | Regeneron Pharma | Modelos de retinosquisis en roedor |
AR111190A1 (es) * | 2017-03-22 | 2019-06-12 | Genentech Inc | Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados |
CN110709096B (zh) * | 2017-05-05 | 2023-10-31 | 泽兰德制药公司 | 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用 |
WO2018232227A1 (en) * | 2017-06-15 | 2018-12-20 | The Trustees Of Columbia University In The City Of New York | Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd |
KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
AU2019262061A1 (en) * | 2018-05-01 | 2020-11-26 | Chibi, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
EP3790863A1 (en) | 2018-05-09 | 2021-03-17 | Akebia Therapeutics Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
WO2020091430A1 (ko) * | 2018-11-02 | 2020-05-07 | 경북대학교 산학협력단 | 황반변성 예방 또는 치료용 조성물 |
CN113226020A (zh) * | 2018-11-14 | 2021-08-06 | 珠海岐微生物科技有限公司 | 用于眼内疾病或病症的动物模型、筛选方法和治疗方法 |
CN111308001A (zh) * | 2018-12-11 | 2020-06-19 | 上海市第一人民医院 | 人黄斑新生血管性疾病的代谢标记物及其应用 |
US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
CA3215235A1 (en) * | 2021-04-13 | 2022-10-20 | Sharon KLIER | Methods of treating retinal vasculopathies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19650215A1 (de) * | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
LT3357911T (lt) * | 2006-06-26 | 2022-08-10 | Akebia Therapeutics Inc. | Prolilo hidroksilazės inhibitoriai ir naudojimo būdai |
WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
CA2837560C (en) * | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
SG10202012791TA (en) * | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
-
2015
- 2015-01-23 WO PCT/US2015/012634 patent/WO2015112831A1/en active Application Filing
- 2015-01-23 US US15/112,954 patent/US20160339005A1/en not_active Abandoned
- 2015-01-23 CN CN201580015037.4A patent/CN106132201A/zh active Pending
- 2015-01-23 JP JP2016548111A patent/JP2017503835A/ja active Pending
- 2015-01-23 RU RU2016133980A patent/RU2016133980A/ru not_active Application Discontinuation
- 2015-01-23 AU AU2015209264A patent/AU2015209264A1/en not_active Abandoned
- 2015-01-23 CA CA2937349A patent/CA2937349A1/en not_active Abandoned
- 2015-01-23 MX MX2016009331A patent/MX2016009331A/es unknown
- 2015-01-23 KR KR1020167022741A patent/KR20160108554A/ko not_active Application Discontinuation
- 2015-01-23 EP EP15740401.3A patent/EP3096617A4/en not_active Withdrawn
-
2016
- 2016-07-14 IL IL246791A patent/IL246791A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3096617A1 (en) | 2016-11-30 |
CA2937349A1 (en) | 2015-07-30 |
JP2017503835A (ja) | 2017-02-02 |
IL246791A0 (en) | 2016-08-31 |
WO2015112831A8 (en) | 2016-09-01 |
KR20160108554A (ko) | 2016-09-19 |
RU2016133980A3 (es) | 2018-10-26 |
EP3096617A4 (en) | 2017-09-13 |
AU2015209264A1 (en) | 2016-08-04 |
CN106132201A (zh) | 2016-11-16 |
WO2015112831A1 (en) | 2015-07-30 |
RU2016133980A (ru) | 2018-03-01 |
US20160339005A1 (en) | 2016-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016009331A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
MX2013003890A (es) | Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas. | |
MX347226B (es) | Tratamiento de enfermedad ocular. | |
SG191334A1 (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
PH12014502449A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
MX2021008663A (es) | Anticuerpos mejorados contra il-6. | |
NZ712030A (en) | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists | |
PH12015501938A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
MX2014005209A (es) | Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas. | |
EP3405159A4 (en) | TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION | |
MX2022001433A (es) | Tratamiento personalizado de enfermedades oftalmologicas. | |
GB2541840A (en) | Ophthalmic composition for the treatment of ocular infection | |
MX2019011925A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
MX2019011242A (es) | Farmacos y composiciones para el tratamiento de trastornos oculares. | |
MX2022006439A (es) | Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva. | |
TW201613596A (en) | Ophthalmic suspension preparation | |
MX2022000554A (es) | Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp. | |
CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
EP3445334A4 (en) | NANOLIPOSOMES FOR PROLONGED ADMINISTRATION OF TACROLIMUS FOR THE TREATMENT OF PREVIOUS SEGMENT OCULAR DISEASES | |
山岸哲哉 et al. | Fundus autofluorescence in polypoidal choroidal vasculopathy. | |
RU2012125938A (ru) | Способ лечения экссудативной формы возрастной макулярной дегенерации |